Physician-scientist. Evidence, drug development, and clinical AI.

Dr. Damon Tojjar

I'm a physician-scientist and digital health entrepreneur. My work runs across global drug development, clinical AI and decision support, and medical-device regulation, and it starts with reading the medical evidence closely. I build clinical tools that are tested in real settings, and I explain the science and the evidence behind modern medicine.

Explore the workRead the research
  • M.D.Lund University
  • StanfordSystems Medicine Fellow
  • ScienceMagnus Blix Award
  • EITTop 20 Deep Tech
0+
Citations to co-authored research, Diabetes Care (paper-level)
0+
Cited expert articles and explainers published
0
Peer-reviewed publications (Tojjar, D.)
Science
Magnus Blix Award for the Science paper

About

A clinician and a scientist, building at the bedside and in code.

Dr. Damon Tojjar is a physician-scientist (M.D., Ph.D. candidate) and digital health entrepreneur whose work spans leading institutions in Europe and the United States. He earned his M.D. at Lund University, whose medical school had the lowest acceptance rate in Sweden at the time of his admission, and achieved top-percentile results on the national medical board examinations. He trained as a Research Fellow in Systems Medicine at Stanford University School of Medicine under Professor Atul Butte, where he was an Anna Lindh Fellow. His doctoral research, based at the Lund University Diabetes Centre, focuses on the genetics of type 2 diabetes.

Bridging research and industry, he served as International Medical Manager and Principal Medical Specialist in global development at Novo Nordisk, helping lead global clinical programs for GLP-1 and insulin therapies, including Tresiba, Ryzodeg, and Xultophy. He co-developed EASY Diabetes, an AI decision-support system that earned Sweden's Medtech4Health Innovation Award, and co-founded Vi-Health, which was selected as one of 20 finalists (Top 20 Deep Tech) in the European Institute of Innovation and Technology's EIT Digital Challenge and was later acquired by Numan. He mentors early-career scientists and founders, including through the Nucleate biotech program and as a mentor with UCLA Ventures, and has served as a board member of Lund University's innovation and holding companies, LU Innovation (now LU Ventures) and LU Holding.

  1. M.D., Lund University
    Broad clinical training.
  2. Research Fellow, Systems Medicine, Stanford
    Diabetes genetics with Professor Atul Butte.
  3. International Medical Manager and Principal Medical Specialist, Novo Nordisk
    Global development of diabetes therapies.
  4. Builder of clinical AI
    EASY Diabetes and Vi-Health.

Expertise

Four areas where clinical depth meets technology.

Diabetes research

A decade of work on the genetics and metabolic biology of type 2 diabetes, with peer-reviewed contributions in Science, Diabetes Care, and Diabetologia.

Clinical decision support

AI-driven decision support that fits real clinical workflows. EASY Diabetes, evaluated in the EASY-1 randomized controlled trial, is the clearest expression.

Healthcare AI

Building and validating AI for symptom triage and chronic-disease management, grounded in clinical evidence and ethical standards rather than hype.

Regulatory and translational strategy

Global development experience at Novo Nordisk plus FDA Clinical Investigator training and KTH training in Medical Device Regulations (EU MDR, IVDR, FDA, SaMD).

Selected work

Ventures and programs, from discovery to deployment.

  1. EASY Diabetes

    Co-developer and Head of Medical and Science

    An AI-based clinical decision-support system for type 2 diabetes, developed with patients, clinicians, and researchers. Its randomized controlled trial, EASY-1 (NCT03258268), compared the system against standard of care. EASY Diabetes received the Medtech4Health Innovation Award.

  2. Vi-Health

    Co-founder and Managing Director

    A digital health company offering an AI symptom checker and e-consultation tools. Vi-Health was selected as one of 20 finalists (Top 20 Deep Tech) in the European Institute of Innovation and Technology's EIT Digital Challenge and was later acquired by Numan.

  3. Novo Nordisk, Global Development

    International Medical Manager and Principal Medical Specialist

    Helped lead global clinical programs for GLP-1, insulin, and combination therapies, including Tresiba, Ryzodeg, and Xultophy, keeping the clinical evidence solid while the work ran across many countries.

Research and publications

Peer-reviewed work on the biology of diabetes.

In formal citations his work appears under the publication name Tojjar, D. His co-authored meta-analysis in Diabetes Care is widely cited (paper-level, 800+ citations), and his shared (co-second) author contribution to the Science study was recognized with the Magnus Blix Award.

  • ScienceOverexpression of alpha2A-adrenergic receptors contributes to type 2 diabetesTojjar, D. (shared / co-second author). Magnus Blix Award.doi.org/10.1126/science.1176827
  • Diabetes CareEthnic differences in the relationship between insulin sensitivity and insulin responseTojjar, D. (co-author). Systematic review and meta-analysis. Widely cited.doi.org/10.2337/dc12-1235
  • DiabetologiaPolymorphisms in the Ca2+ channel CaV2.3 (CACNA1E) and type 2 diabetesTojjar, D. (co-author). Gene discovery and impaired insulin secretion.doi.org/10.1007/s00125-007-0846-2
  • Diabetes, Obesity and MetabolismComparison of insulin degludec with insulin detemir in type 1 diabetesTojjar, D. (co-author). One-year treat-to-target trial.doi.org/10.1111/dom.12573

Recognition and roles

Awards, fellowships, and advisory work.

Awards

  • Magnus Blix Award, for the Science publication
  • Medtech4Health Innovation Award, for EASY Diabetes
  • EIT Digital Challenge Top 20 Deep Tech finalist, for Vi-Health

Fellowships and training

  • Research Fellow in Systems Medicine, Stanford
  • Anna Lindh Fellow, Stanford
  • Harvard T.H. Chan health-outcomes course
  • FDA Clinical Investigator training
  • Medical Device Regulations training, KTH

Board, advisory and mentorship

  • Nucleate biotech mentor
  • Mentor, UCLA Ventures
  • Board member, LU Innovation (now LU Ventures) and LU Holding, Lund University
  • Council member, Swedish Association of Family Medicine (quality and patient safety)
  • Grant reviewer, Pivotal Philanthropies Action for Women's Health
  • Selected participant, Prince Daniel's Fellowship program (IVA)

Frequently asked

Questions about Dr. Damon Tojjar.

Who is Dr. Damon Tojjar?

Dr. Damon Tojjar is a physician-scientist and digital health entrepreneur who works across diabetes research, clinical medicine, and AI-driven care. He holds an M.D. from Lund University and is a Ph.D. candidate in medical science.

What are his credentials?

He earned a Doctor of Medicine (M.D.) at Lund University and is a Ph.D. candidate conducting doctoral research at the Lund University Diabetes Centre. His training includes a Research Fellowship in Systems Medicine at Stanford, FDA Clinical Investigator training, and Medical Device Regulations training at KTH.

What is EASY Diabetes?

EASY Diabetes is an AI-based clinical decision-support system for type 2 diabetes that Dr. Tojjar co-developed and led as Head of Medical and Science. Its randomized controlled trial, EASY-1 (NCT03258268), compared the system against standard of care. The system received the Medtech4Health Innovation Award.

What does he research?

His research focuses on type 2 diabetes genetics and metabolic health, and on applying AI and clinical decision support to chronic disease management. His peer-reviewed work appears in Science, Diabetes Care, Diabetologia, and Diabetes, Obesity and Metabolism, published under the name Tojjar, D.

Contact

Get in touch.

For research collaboration, advisory work, speaking, or mentorship inquiries, reach out directly. Messages are read personally.

contact@damontojjar.com

You can also find Dr. Tojjar through his verified scholarly and professional profiles linked below.